- Carfilzomib - the selective proteasome inhibitor, the further expectation for the patients with the multiple myeloma2016 | Faculty of Medicine in Hradec Králové
- Diagnosis and treatment of multiple myeloma2014 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Carfilzomib, a selective proteasome inhibitor - new possibility in multiple myeloma treatment2016 | Faculty of Medicine in Hradec Králové
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma2015 | Faculty of Medicine in Hradec Králové
- Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment2017 | First Faculty of Medicine
- A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor2016 | Faculty of Pharmacy in Hradec Králové
- Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study2017 | First Faculty of Medicine
- A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)2017 | Faculty of Medicine in Hradec Králové
- Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study2023 | First Faculty of Medicine
- Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data2020 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis2022 | First Faculty of Medicine
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial2021 | First Faculty of Medicine
- Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma2016 | Faculty of Medicine in Hradec Králové
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study2016 | Publication without faculty affiliation
- Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis2022 | First Faculty of Medicine
- Novinky v léčbě mnohočetného myelomu v roce 20172018 | First Faculty of Medicine
- In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline2019 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma2016 | Publication without faculty affiliation
- Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study2018 | Faculty of Medicine in Hradec Králové
- Proteasome inhibitors in the treatment of multiple myeloma2021 | Faculty of Medicine in Hradec Králové
- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study2020 | First Faculty of Medicine
- Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma2020 | First Faculty of Medicine, Faculty of Science, Faculty of Physical Education and Sport
- Multiple myeloma - are we in 2020 able to cure the patient?2020 | First Faculty of Medicine
- Komentář ke studii (Karfilzomib, lenalidomid a dexamethason v léčbě pacientů s relabujícím mnohočetným myelomem - studie ASPIRE)2016 | First Faculty of Medicine
- Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma2018 | First Faculty of Medicine
- Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma2016 | Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PX-171-009Publication without faculty affiliation
- Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies2023 | First Faculty of Medicine
- Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA2022 | First Faculty of Medicine
- AL amyloidosis: advances in diagnostics and treatment2019 | First Faculty of Medicine